The Lewis lab research interests are focused on the development of radiopharmaceuticals for targeted diagnosis and treatment of cancer. By combining small- and biomolecule-based targeting agents with positron-emitting or therapeutic radioisotopes, we can interrogate molecular profiles of cancer using noninvasive nuclear imaging or treat tumors specifically with endoradiotherapy. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides, with an emphasis on developing these novel radiopharmaceuticals for clinical translation. A few examples of our work are given below.
Jason S. Lewis, PhD
Emily Tow Jackson Chair in Oncology
Research FocusRadiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.
EducationPhD, The University of Kent (UK)
- Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the Pharmacological Properties of a Metabolic PET Tracer in Prostate Cancer, Proceedings of the National Academy of Sciences (PNAS), 111, 7254-7259, 2014.
- Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko SK, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS*, Thompson CB*. Glutamine Based PET Imaging Facilitates Enhanced Metabolic Evaluation of Gliomas In Vivo. Science Translational Medicine, 7, 274ra17, 2015.
- Distinguished Investigator Award, Academy Radiology Research (2014)
- Fellow, World Molecular Imaging Society (FWMIS) (2015)
- Michael J. Welch Award, SNMMI (2017)
- Fellow, Society of Nuclear Medicine and Molecular Imaging (FSNMMI) (2019)
- Paul C. Aebersold Award, ERF-SNMMI (2019)
- NCI R35 Outstanding Investigator Award (2019-2026)